

SA Health

# Cancer Chemotherapy Protocol Registration Form and Template

SA Health Cancer Drug Committee

July 2017



Government  
of South Australia

SA Health

### Applicant Details

Consultant Name: Dr Vy Broadbridge	
Position: Medical Oncologist	
Clinical Unit, Hospital/LHN: Medical Oncology, TQEH/CALHN	
Telephone: 8222 7096	Pager:
Mobile:	Email: <a href="mailto:Vy.Broadbridge@sa.gov.au">Vy.Broadbridge@sa.gov.au</a>

### Supporting Tumour Stream Lead Details

Consultant Name: Prof Tim Price	
Position: Medical Oncologist	
Clinical Unit, Hospital/LHN: Medical Oncology, TQEH/CALHN	
Telephone:	Pager:
Mobile:	Email: <a href="mailto:Timothy.Price@sa.gov.au">Timothy.Price@sa.gov.au</a>

### Supporting Specialist Pharmacist Details

Name: Dale Thompson	
Position: Deputy Director of Pharmacy	
Clinical Unit, Hospital/LHN: RAH/CALHN	
Telephone: 7074 0135	Pager:
Mobile:	Email: <a href="mailto:Dale.Thompson2@sa.gov.au">Dale.Thompson2@sa.gov.au</a>

### Supporting Specialist Nurse Details

Name: Kristin Linke	
Position: Nurse Practitioner	
Clinical Unit, Hospital/LHN: Medical Oncology, TQEH/CALHN	
Telephone:	Pager:
Mobile:	Email: <a href="mailto:Kristin.Linke@sa.gov.au">Kristin.Linke@sa.gov.au</a>

### SA Health Cancer Drug Committee Use only:

Application received (date):	
Confirmation of costing confirmed* <input type="checkbox"/>	
Approval Status	
APPROVED <input type="checkbox"/>	
Conditions of approval (if any):	
REJECTED <input type="checkbox"/>	
Reason(s) for rejection:	
Treatment Risk Level allocated:	
SAH-CDC comments (if any)	
I acknowledge the application and to the best of my knowledge the information contained within is correct and confirm the decision made by the SA Health Cancer drug Committee in submitting this protocol to the SA Health Approved Cancer Chemotherapy Protocol Register:	
SAH-CDC Chair (or delegate):	Position:
Signature:	Date:

<b>Protocol Name</b>	
<b>Protocol Number</b>	

# Metastatic Colorectal Cancer – Irinotecan and Panitumumab

## Treatment Schedule - Summary

Drug	Dose	Route	Day
Panitumumab	6mg/kg	IV	Day 1
Irinotecan	180mg/m <sup>2</sup>	IV	Day 1

Frequency: every 14 days

Notes (e.g. 1<sup>st</sup> line treatment, alternate scheduling options):

Number of Cycles: ongoing until disease progression/unacceptable toxicity

## Protocol

Indications and Patient Population: RAS wild-type metastatic colorectal cancer

Indications for use: RAS wild-type metastatic colorectal cancer

Exclusions (e.g. low GFR):

**Notes:** All patients should be tested for RAS mutations. Patients with mutant or unknown RAS status should not receive an EGFR antagonist as it may be harmful. Presence of a BRAF mutation has been identified as a marker of poorer prognosis, and potentially predictive of resistance to EGFR antagonists

## Drug Status (PBS status, formulation etc.):

All agents are TGA, PBS and SAFC listed

## Clinical Information:

As per eviQ monographs for individual agents:

- <https://www.eviq.org.au/medical-oncology/colorectal/metastatic/85-colorectal-metastatic-irinotecan-three-weekly>
- <https://www.eviq.org.au/medical-oncology/colorectal/metastatic/101-colorectal-metastatic-panitumumab>

## Treatment Schedule - Detailed

Drug	Dose	Administration/frequency
Dexamethasone	8mg	IV/PO Day 1 to Day 3
Palonosetron	0.25mg	IV Day 1
Panitumumab	6mg/kg	IV Day 1
Irinotecan	180mg/m <sup>2</sup>	IV Day 1

**Frequency: 14 days**

**Number of Cycles:** Continuous until disease progression/unacceptable toxicity

## Dose Modifications:

As per eviQ monographs for individual agents:

- <https://www.eviq.org.au/medical-oncology/colorectal/metastatic/85-colorectal-metastatic-irinotecan-three-weekly>
- <https://www.eviq.org.au/medical-oncology/colorectal/metastatic/101-colorectal-metastatic-panitumumab>

## Interactions:

As per eviQ monographs for individual agents:

- <https://www.eviq.org.au/medical-oncology/colorectal/metastatic/85-colorectal-metastatic-irinotecan-three-weekly>
- <https://www.eviq.org.au/medical-oncology/colorectal/metastatic/101-colorectal-metastatic-panitumumab>

## General Interactions

As per eviQ monographs for individual agents:

- <https://www.eviq.org.au/medical-oncology/colorectal/metastatic/85-colorectal-metastatic-irinotecan-three-weekly>
- <https://www.eviq.org.au/medical-oncology/colorectal/metastatic/101-colorectal-metastatic-panitumumab>

## Administration details

As per eviQ monographs for individual agents:

- <https://www.eviq.org.au/medical-oncology/colorectal/metastatic/85-colorectal-metastatic-irinotecan-three-weekly>
- <https://www.eviq.org.au/medical-oncology/colorectal/metastatic/101-colorectal-metastatic-panitumumab>

## Monitoring

As per eviQ monographs for individual agents:

- <https://www.eviq.org.au/medical-oncology/colorectal/metastatic/85-colorectal-metastatic-irinotecan-three-weekly>
- <https://www.eviq.org.au/medical-oncology/colorectal/metastatic/101-colorectal-metastatic-panitumumab>

## Side-effects

As per eviQ monographs for individual agents:

- <https://www.eviq.org.au/medical-oncology/colorectal/metastatic/85-colorectal-metastatic-irinotecan-three-weekly>
- <https://www.eviq.org.au/medical-oncology/colorectal/metastatic/101-colorectal-metastatic-panitumumab>

## Supporting Documents

[Existing pdf prescription template CHE-04536](#)

---

## For more information

Medicines and Technology Programs (MTP) and Out of Hospital Pharmacy Services  
Department for Health and Ageing  
Level 8, Citi Centre  
11 Hindmarsh Square  
Adelaide, SA 5000  
Telephone: +61 8 8226 7080  
[www.sahealth.sa.gov.au](http://www.sahealth.sa.gov.au)



[www.ausgoal.gov.au/creative-commons](http://www.ausgoal.gov.au/creative-commons)



Government  
of South Australia

SA Health